Inflammatory Bowel Disease
Longitudinal Care
Managing Crohn disease and ulcerative colitis over time: induction, maintenance, monitoring, and surveillance.
What Is IBD?
Inflammatory bowel disease is a group of chronic, relapsing-remitting immune-mediated disorders of the gastrointestinal tract. The two main forms are Crohn disease (CD) and ulcerative colitis (UC).
The Relapsing-Remitting Course
Two Phases: Induction & Maintenance
The Treatment Ladder
Core Rule: Treat-to-Target
Don't just treat symptoms. Set objective targets and adjust therapy until they're met. Targets are checked at intervals using a composite of measures:
Distinction: CD vs UC
| Crohn Disease | Ulcerative Colitis | |
|---|---|---|
| Location | Mouth to anus, skip lesions | Colon only, continuous |
| Depth | Transmural | Mucosa / submucosa |
| Complications | Fistulas, strictures, abscess | Toxic megacolon, dysplasia |
| Smoking | Worsens disease | Paradoxically protective |
| Cure by surgery | No (recurs) | Yes (colectomy) |
| 5-ASA role | Limited | Mainstay for mild-moderate |
Drug Safety Monitoring
A Step-by-Step Approach
Worked Example: Steroid Dependence
A 28-year-old with ileal Crohn disease flares each time prednisone is tapered below 15 mg. He has had 3 flares in the past year while on 5-ASA only.
Worked Example: Surveillance
A 45-year-old has had extensive ulcerative colitis for 9 years, currently in remission. She asks how often she needs colonoscopy.
Worked Example: Acute Severe Flare
A 22-year-old with UC has 10 bloody stools/day, fever, tachycardia, and abdominal distension. CRP is markedly elevated.
Longitudinal Health Maintenance
Common Mistakes
Summary: Drug Roles
| Agent | Induction | Maintenance |
|---|---|---|
| Corticosteroids | Yes | No |
| 5-ASA (UC) | Yes (mild) | Yes (UC) |
| Thiopurines | Slow onset | Yes |
| Anti-TNF biologics | Yes | Yes |
| Methotrexate | Yes (CD) | Yes (CD) |
Question 1 of 5
A 30-year-old with Crohn disease has flared 3 times this year, each requiring prednisone, and cannot taper below 20 mg without relapse. What is the most appropriate next step?
Question 2 of 5
Before initiating an anti-TNF biologic such as infliximab, which screening is most essential?
Question 3 of 5
A patient with extensive ulcerative colitis was diagnosed 8 years ago and is in remission. What surveillance is recommended?
Question 4 of 5
A 22-year-old with UC is admitted with 12 bloody stools/day, fever, and abdominal distension. Which order should be avoided?
Question 5 of 5
In a treat-to-target strategy for IBD, which finding best confirms an optimal treatment response?